207 related articles for article (PubMed ID: 32685598)
1. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
J Health Econ Outcomes Res; 2020; 7(1):52-60. PubMed ID: 32685598
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
[TBL] [Abstract][Full Text] [Related]
3. Sickle cell disease complications: Prevalence and resource utilization.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
[TBL] [Abstract][Full Text] [Related]
4. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
Shah NR; Bhor M; Latremouille-Viau D; Kumar Sharma V; Puckrein GA; Gagnon-Sanschagrin P; Khare A; Kumar Singh M; Serra E; Davidson M; Xu L; Guerin A
J Med Econ; 2020 Nov; 23(11):1345-1355. PubMed ID: 32815766
[TBL] [Abstract][Full Text] [Related]
5. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
[TBL] [Abstract][Full Text] [Related]
6. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
[TBL] [Abstract][Full Text] [Related]
7. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
[No Abstract] [Full Text] [Related]
8. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
Leleu H; Arlet JB; Habibi A; Etienne-Julan M; Khellaf M; Adjibi Y; Pirenne F; Pitel M; Granghaud A; Sinniah C; De Montalembert M; Galacteros F
PLoS One; 2021; 16(7):e0253986. PubMed ID: 34242255
[TBL] [Abstract][Full Text] [Related]
10. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study.
Kanter J; Bhor M; Li X; Li FY; Paulose J
J Health Econ Outcomes Res; 2019; 6(3):174-184. PubMed ID: 32685589
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
Gallagher ME; Chawla A; Brady BL; Badawy SM
J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
[TBL] [Abstract][Full Text] [Related]
12. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Laboratory Predictors of Painful Vaso-Occlusive Crisis Among Sickle Cell Disease Patients: A Single-Center Study in Saudi Arabia.
Zakaria O; Buhalim RA; Almulhim F; Al Jabr FA; Alrashid A; Almutairi M
Cureus; 2021 May; 13(5):e14980. PubMed ID: 34123674
[TBL] [Abstract][Full Text] [Related]
14. Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies.
Coyne KS; Currie BM; Callaghan M; Wyrwich KW; Pease S; Baker CL; Arkin S; Pittman DD
Eur J Haematol; 2022 Sep; 109(3):226-237. PubMed ID: 35569114
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
J Health Econ Outcomes Res; 2019; 6(3):106-117. PubMed ID: 32685584
[TBL] [Abstract][Full Text] [Related]
16. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease.
Zaidi AU; Glaros AK; Lee S; Wang T; Bhojwani R; Morris E; Donohue B; Paulose J; Iorga ŞR; Nellesen D
Orphanet J Rare Dis; 2021 Nov; 16(1):460. PubMed ID: 34727959
[TBL] [Abstract][Full Text] [Related]
17. Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study.
Rollé A; Vidal E; Laguette P; Garnier Y; Delta D; Martino F; Portecop P; Etienne-Julan M; Piednoir P; De Jong A; Romana M; Bernit E
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138299
[No Abstract] [Full Text] [Related]
18. Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease.
Cieri-Hutcherson NE; Hutcherson TC; Conway-Habes EE; Burns BN; White NA
Pharmacotherapy; 2019 Nov; 39(11):1095-1104. PubMed ID: 31505045
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adenotonsillectomy in reducing obstructive sleep apnea, cerebrovascular ischemia, vaso-occlusive pain, and ACS episodes in pediatric sickle cell disease.
Tripathi A; Jerrell JM; Stallworth JR
Ann Hematol; 2011 Feb; 90(2):145-50. PubMed ID: 20714723
[TBL] [Abstract][Full Text] [Related]
20. Effect of Weather on Frequency of Vaso-Occlusive Crisis in Children With Sickle Cell Disease.
Almuqamam M; Ahuja K; Wassef I; Kilaikode S; Sedrak A
Cureus; 2021 Aug; 13(8):e17254. PubMed ID: 34540479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
